Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds

Rhea-AI Summary

Sanara MedTech (Nasdaq: SMTI) announced publication of a peer-reviewed Journal of Medical Economics study (March 11, 2026) evaluating CellerateRX Surgical Powder for high-risk spine surgery wounds. The one-year economic model (2025 USD) found $3,852 cost savings, a 0.007 QALY gain, and a $4,542 net monetary benefit per patient; readmissions and revisions accounted for $2,238 and $835 of savings. Probabilistic analysis showed dominance in >99% of simulations.

Positive

• Cost savings of $3,852 per high-risk spine surgery patient
• Health gain of 0.007 QALY per patient over one year
• Net monetary benefit of $4,542 per patient
• Avoided hospital readmissions and revisions contributed $2,238 and $835 respectively
• Dominant cost-effectiveness in >99% of probabilistic simulations

Negative

• QALY gain is modest at 0.007, a small absolute health benefit per patient
• Findings derive from an economic model with a one-year horizon rather than a prospective randomized trial

News Market Reaction – SMTI

-0.46%

1 alert

-0.46% News Effect

On the day this news was published, SMTI declined 0.46%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cost savings per patient: $3,852 QALY gain per patient: 0.007 QALYs Net monetary benefit: $4,542 +5 more

8 metrics

Cost savings per patient $3,852 CellerateRX arm vs standard of care over one-year horizon

QALY gain per patient 0.007 QALYs Clinical efficacy of CellerateRX arm over one year

Net monetary benefit $4,542 Incremental benefit of CellerateRX vs standard of care

Readmission cost savings $2,238 Savings from avoided hospital readmissions with CellerateRX

Revision procedure savings $835 Savings from fewer surgical revision procedures

Dominant simulations More than 99% Probabilistic analysis where CellerateRX was cost-effective vs standard care

FY 2025 revenue $102.7M–$103.2M Unaudited preliminary full-year 2025 results (~19% growth)

2026 revenue guidance $116M–$121M Full-year 2026 revenue outlook (+13%–17% vs 2025 midpoint)

Market Reality Check

Price: $19.48 Vol: Volume 88,606 is 1.34x th...

normal vol

$19.48 Last Close

Volume Volume 88,606 is 1.34x the 20-day average of 65,989, showing elevated trading ahead of this publication. normal

Technical Shares at $19.69 are trading below the 200-day MA of $26.58 and sit 45.23% under the 52-week high.

Peers on Argus

SMTI fell 5.06% while peers were mixed: ANGO rose 2.23%, EMBC, KMTS, OSUR and ST...

SMTI fell 5.06% while peers were mixed: ANGO rose 2.23%, EMBC, KMTS, OSUR and STXS were down modestly. No peers appeared in the momentum scanner and no same-day peer headlines were recorded, pointing to a stock-specific move rather than a sector-wide shift.

Historical Context

5 past events · Latest: Mar 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Earnings date notice	Neutral	+1.8%	Scheduled date and call details for upcoming Q4 and FY 2025 results.
Feb 17	Conference participation	Neutral	+0.9%	Announcement of management presentation at TD Cowen health care conference.
Jan 23	Prelim earnings, guidance	Positive	-2.3%	Preliminary Q4/FY 2025 results and introduction of 2026 revenue guidance.
Jan 07	Commercial contract	Positive	+2.8%	Vizient Innovative Technology contract for BIASUR surgical solution at set terms.
Dec 10	Product pipeline update	Positive	+3.3%	Update on OsStic™ bio-adhesive progress and regulatory/patent milestones.

Pattern Detected

Recent news has mostly aligned with price moves, with one notable divergence on preliminary financials and guidance.

Recent Company History

Over the last six months, SMTI has issued several operational and financial updates. Preliminary Q4/FY 2025 results and 2026 guidance on Jan 23 led to a small decline despite highlighting double-digit growth. Commercial milestones like the Vizient Innovative Technology contract for BIASUR and the OsStic™ development update on Dec 10 saw positive price reactions. Today’s peer-reviewed CellerateRX study adds another clinically focused data point supporting the company’s wound management portfolio.

Market Pulse Summary

This announcement highlights peer-reviewed evidence that CellerateRX produced per-patient savings of...

Analysis

This announcement highlights peer-reviewed evidence that CellerateRX produced per-patient savings of $3,852 and a 0.007 QALY gain, supporting both economic and clinical value in high-risk spine surgery. In recent months, SMTI has also reported strong preliminary growth and secured contracts and pipeline milestones. Investors may focus on how this publication influences surgeon adoption, integration into care pathways, and future financial updates such as the upcoming 2025 results.

Key Terms

quality-adjusted life years, QALYs, economic modeling, cohort, +2 more

6 terms

quality-adjusted life years medical

"The clinical efficacy of each treatment arm over this period was measured in quality-adjusted life years"

A quality-adjusted life year (QALY) is a single measure that combines how many years of life a medical treatment adds with the quality of those years, where one QALY equals one year in perfect health. Health economists and payers use QALYs like a cost-per-mile metric to compare treatments, so they matter to investors because QALY-based assessments influence pricing, reimbursement and the commercial value of therapies.

QALYs medical

"measured in quality-adjusted life years (“QALYs”), while the direct medical costs"

Quality-adjusted life years (QALYs) measure how much a medical treatment extends life while accounting for the quality of that additional life, by weighting each year with a score from 0 (equivalent to death) to 1 (perfect health). Think of it as counting miles driven adjusted for road smoothness: more and smoother miles are more valuable. Investors watch QALYs because health technology assessments and payers use them to decide whether treatments are worth funding, which directly influences pricing, market access, and revenue potential.

economic modeling technical

"researchers utilized economic modeling to evaluate the clinical outcomes and direct medical costs"

Economic modeling is building a simplified, number-based version of how an economy, industry, or company behaves to estimate future outcomes like growth, demand, costs, or profits. Investors use these models like a weather forecast or financial roadmap—they turn complex forces into scenarios that help weigh risks, test assumptions, and guide decisions about buying, selling, or valuing assets. The quality of the model affects how reliable those investment choices are.

cohort medical

"direct medical costs of a cohort of high-comorbidity patients undergoing complex spinal surgery"

A cohort is a group of people, customers, or study participants who share a specific characteristic or experience within a defined time frame—for example, patients given the same treatment or customers who started using a service in the same month. Investors use cohort analysis to track performance, revenue patterns, or risks over time, much like comparing different batches of a product to see which approaches produce lasting results.

probabilistic analysis technical

"In a probabilistic analysis conducted as part of the study, the CellerateRX treatment arm"

Probabilistic analysis uses ranges and assigned chances instead of single guesses to estimate future outcomes, recognizing uncertainty in forecasts like revenue, costs, or project success. For investors it turns vague 'what if' questions into measurable risks and likely results, helping compare scenarios, set realistic valuations, and decide how much to risk — much like a weather forecast gives probabilities for rain so you can plan whether to carry an umbrella.

net monetary benefit financial

"0.007 QALY gain per patient, yielding a net monetary benefit of $4,542."

Net monetary benefit is the dollar value of the gain from a project, treatment, or transaction after subtracting its costs and other trade-offs; in health economics it often means the money-equivalent value of improved outcomes minus the expense of delivering them. Investors care because it translates abstract benefits into a single cash-based measure of value creation or loss — like checking the pocket change left after paying for something to judge whether the purchase was worth it.

AI-generated analysis. Not financial advice.

Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX^® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone

FORT WORTH, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX^® Surgical Powder (“CellerateRX”) in the Journal of Medical Economics. The study estimated the cost-effectiveness of adding CellerateRX as an adjunct to the standard of care for reducing postoperative complications in high-risk spinal surgery patients.

“We are pleased to see the publication of this peer-reviewed study, which represents an important addition to the compelling body of clinical evidence supporting CellerateRX’s value proposition in the management of surgical wounds,” said Seth Yon, Sanara’s President and Chief Executive Officer. “Its findings demonstrate the significant reductions in medical costs and improvements in health outcomes that can be achieved using CellerateRX to manage acute surgical wounds following spine surgery for high-risk patients. Sanara remains committed to bringing clinically effective, cost-saving solutions like CellerateRX to surgeons and their patients, and we look forward to raising awareness of this new publication in the marketplace.”

The study’s researchers utilized economic modeling to evaluate the clinical outcomes and direct medical costs of a cohort of high-comorbidity patients undergoing complex spinal surgery procedures. They classified patients into two treatment arms: 1) those treated with CellerateRX as an adjunct to the standard of care, and 2) those treated with the standard of care alone, for the management of acute surgical wounds following spine surgery.

Based on the published clinical literature for each treatment arm, researchers evaluated the incidence of post-operative complications, hospital readmissions and surgical revision procedures over a one-year time horizon. The clinical efficacy of each treatment arm over this period was measured in quality-adjusted life years (“QALYs”), while the direct medical costs were measured in 2025 U.S. dollars.

The researchers found that the group treated with CellerateRX exhibited a dominant cost-effectiveness profile compared to the group treated with the standard of care alone. Specifically, the CellerateRX treatment arm generated $3,852 in cost savings and a 0.007 QALY gain per patient, yielding a net monetary benefit of $4,542. The primary contributors to cost savings were the avoidance of hospital readmissions and surgical revision procedures, which conservatively accounted for $2,238 and $835 of the total cost reductions, respectively. In a probabilistic analysis conducted as part of the study, the CellerateRX treatment arm was found to have the dominant cost-effectiveness profile compared to treatment with the standard of care alone in more than 99% of clinical variability simulations.

Based on these findings, the researchers concluded that CellerateRX can promote both improved health outcomes and cost savings compared to the standard of care alone for wound management in high-risk spinal surgery populations. They added that their findings support CellerateRX as a value-enhancing component of the spine surgery care pathway, particularly for patients with elevated complication risk.

The published study may be accessed via the following link: https://doi.org/10.1080/13696998.2026.2639234

About Sanara MedTech Inc.

Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company’s products and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara’s products are primarily sold in the North American surgical tissue repair market. Sanara markets and distributes CellerateRX^® Surgical Activated Collagen^® Powder, BIASURGE^® Advanced Surgical Solution, FORTIFY TRG^® Tissue Repair Graft and FORTIFY FLOWABLE^® Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN^® Verified Inductive Bone Matrix, ALLOCYTE^® Plus Advanced Viable Bone Matrix, BiFORM^® Bioactive Moldable Matrix and TEXAGEN^® Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit SanaraMedTech.com.

Information about Forward-Looking Statements

The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expects,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s business strategy and mission, the development of new products, the timing of commercialization of the Company’s products, and the regulatory approval process. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.

All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.

Investor Relations Contact:

Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com

FAQ

What did Sanara (SMTI) report about CellerateRX cost savings in the March 11, 2026 study?

The study reported $3,852 in direct cost savings per high-risk spine surgery patient. According to the company, avoided readmissions and surgical revisions were the main drivers, contributing $2,238 and $835 of savings respectively.

How much health benefit did CellerateRX provide in the Journal of Medical Economics study for SMTI?

The study found a 0.007 QALY gain per patient over one year when adding CellerateRX to standard care. According to the company, this reflects improved outcomes from fewer complications, readmissions, and revision surgeries.

What is the reported net monetary benefit per patient for CellerateRX in the SMTI study?

The analysis showed a $4,542 net monetary benefit per high-risk spine surgery patient. According to the company, this combines direct cost savings and the estimated value of quality-adjusted life year improvements.

Where was the CellerateRX economic and clinical value study for SMTI published and what timeframe was used?

The peer-reviewed study was published in the Journal of Medical Economics and used a one-year time horizon with costs measured in 2025 U.S. dollars. According to the company, the model evaluated postoperative complications and readmissions.

What level of certainty did the SMTI study report for CellerateRX's cost-effectiveness?

Probabilistic analysis showed CellerateRX was dominant in more than 99% of clinical variability simulations. According to the company, this indicates robust model results across simulated parameter uncertainty.